Robert J. Motzer, MD

Oncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.

Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.

Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.

Experts detail their approaches to dosing combination lenvatinib and pembrolizumab for patients with advanced RCC, emphasizing individualized treatment for balanced efficacy and toxicity.

Elizabeth Plimack, MD, and Robert Motzer, MD, explain their preferences between TKI-IO combination therapies for patients with advanced RCC considering efficacy, side effects, and specific patient factors.

Medical oncologists discuss a patient's surprising rapid decline after an initial diagnosis of clear cell RCC, emphasizing the efficacy of combination lenvatinib/pembrolizumab in similar patients.

Robert Motzer, MD, presents the patient profile of a 65-year-old man diagnosed with clear cell RCC for discussion.

Looking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.

A brief review of the clinical rationale behind therapeutic regimens used for patients with non-clear cell carcinoma.

Experts review a clinical scenario of non–clear cell renal cell carcinoma, wherein the patient is managed with cabozantinib-nivolumab.

A brief discussion on the genetic risk tied to clear cell renal cell carcinoma and how that may inform familial risk and testing.

Expert perspectives on the possible roles of neoadjuvant nivolumab and adjuvant sunitinib for patients with renal cell carcinoma.

A clinical scenario of renal cell carcinoma treated with surgery and adjuvant pembrolizumab is reviewed by a panel of experts.

Expert perspectives on lenvatinib/pembrolizumab combination therapy in renal cell carcinoma, including appropriate dosing and adverse event management.

Shared insight on the patient and disease factors that inform the selection of therapy for favorable-risk renal cell carcinoma.

A second clinical scenario focusing on favorable-risk renal cell carcinoma managed with lenvatinib-pembrolizumab therapy.

A brief discussion on triplet therapy being investigated in patients with intermediate- and poor-risk renal cell carcinoma.

Focusing on immunotherapy in the setting of intermediate- and poor-risk renal cell carcinoma, panelists review toxicity management and duration of response.

Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolumab and nivolumab maintenance.

Robert J. Motzer, MD, discusses the efficacy of cabozantinib in patients with renal cell carcinoma.

Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, discusses the first-line treatment landscape of metastatic clear cell renal cell carcinoma.

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab plus ipilimumab in the treatment of patients with renal cell carcinoma.

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the explosion of immunotherapy in the landscape of renal cell carcinoma (RCC).

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.